Biomarkers for PD-1/PD-L1 Blockade Therapy in Non–Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection?

Clinical Lung Cancer

Volumn 17, Issue 5, 2016, Pages 350-361

  Chae, Young Kwang ^a,b   Pan, Alan ^b   Davis, Andrew A ^b   Raparia, Kirtee ^b   Mohindra, Nisha A ^a,b   Matsangou, Maria ^a,b   Giles, Francis J ^a,b  

^a Northwestern University Feinberg School of Medicine   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Biomarkers; Immunotherapy; NSCLC; Programmed cell death 1 protein ligand; Programmed cell death 1 protein receptor

Indexed keywords

ATEZOLIZUMAB; AVELUMAB; BIOLOGICAL MARKER; BMS 936559; DOCETAXEL; DURVALUMAB; MONOCLONAL ANTIBODY; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; T LYMPHOCYTE RECEPTOR; TICILIMUMAB; ANTINEOPLASTIC AGENT; TUMOR MARKER;

CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CLONAL VARIATION; CONSENSUS; HUMAN; IMMUNOHISTOCHEMISTRY; MONOTHERAPY; NON SMALL CELL LUNG CANCER; NONHUMAN; PATIENT SELECTION; PERSONALIZED MEDICINE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SOMATIC MUTATION; T LYMPHOCYTE; TREATMENT OUTCOME; TUMOR MICROENVIRONMENT; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; LUNG NEOPLASMS; PATHOLOGY; PROCEDURES;

ANTIGENS, CD274; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; PATIENT SELECTION; PROGRAMMED CELL DEATH 1 RECEPTOR; TUMOR MICROENVIRONMENT;

EID: 84964677982     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2016.03.011     Document Type: Review

References (64)

1. 1 Velcheti, V., Schalper, K.A., Carvajal, D.E., et al. Programmed death ligand-1 expression in non-small cell lung cancer. Lab Invest 94 (2014), 107–116.
2. 2 Detterbeck, F.C., Boffa, D.J., Tanoue, L.T., The new lung cancer staging system. Chest 136 (2009), 260–271.
3. 3 Pardoll, D.M., The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12 (2012), 252–264.
4. 4 Brahmer, J.R., Tykodi, S.S., Chow, L.Q., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366 (2012), 2455–2465.
5. 5 Topalian, S.L., Hodi, F.S., Brahmer, J.R., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366 (2012), 2443–2454.
6. 6 Postow, M.A., Chesney, J., Pavlick, A.C., et al. Nivolumab and Ipilimumab versus Ipilimumab in untreated melanoma. N Engl J Med, 8, 2015, 123.
7. 7 Sharma, P., Allison, J.P., The future of immune checkpoint therapy. Science 348 (2015), 56–61.
8. 8 Lawrence, M.S., Stojanov, P., Polak, P., et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499 (2013), 214–218.
9. 9 Hamid, O., Robert, C., Daud, A., et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369 (2013), 134–144.
10. 10 Brahmer, J., Horn, L., Gandhi, L., et al. Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients (pts) with advanced non-small cell lung cancer: survival and clinical activity by subgroup analysis. Presented at the ASCO meeting, Chicago, IL, abstract 8112, 2014 J Clin Oncol, 32, 2014, 5s.
11. 11 Gettinger, S.N., Horn, L., Gandhi, L., et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 33 (2015), 2004–2012.
12. 12 Rizvi, N.A., Mazieres, J., Planchard, D., et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol 16 (2015), 257–265.
13. 13 Brahmer, J., Reckamp, K.L., Baas, P., et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373 (2015), 123–135.
14. 14 Borghaei, H., Paz-Ares, L., Horn, L., et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373 (2015), 1627–1639.
15. 15 Sakai, H., Nishio, M., Hida, T., et al. Phase II studies of nivolumab in patients with advanced squamous (SQ) or non-squamous (NSQ) non-small cell lung cancer (NSCLC). Poster presented at the European Cancer Congress, Vienna, Austria, 2015; abstract 521 Eur J Cancer 51:suppl 3 (2015), S110–S111.
16. 16 Garon, E.B., Rizvi, N.A., Hui, R., et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372 (2015), 2018–2028.
17. 17 Herbst, R.S., Baas, P., Kim, D.W., et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387 (2015), 1540–1550.
18. 18 Patnaik, A., Socinski, M., Gubens, M., et al. Phase 1 study of pembrolizumab plus ipilimumab as second-line therapy for advanced non-small cell lung cancer: KEYNOTE-021 cohort D. Poster presented at the 51st American Society of Clinical Oncology (ASCO) Annual Meeting, May 29 to June 2, Chicago, IL, 2015 J Clin Oncol, 33(suppl), 2015 abstract 8011.
19. 19 Herbst, R.S., Soria, J.C., Kowanetz, M., et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515 (2014), 563–567.
20. 20 Liu, S.V., Powderly, J.D., Camidge, D.R., et al. Safety and efficacy of MPDL3280A (anti-PDL1) in combination with platinum-based doublet chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol, 33, 2015 abstract 8030.
21. 21 Spigel, D., Chaft, J., Gettinger, S., et al. Clinical activity and safety from a phase II study (FIR) of MPDL3280A (anti-PDL1) in PD-L1–selected patients with non-small cell lung cancer (NSCLC). Poster presented at the 51st American Society of Clinical Oncology (ASCO) Annual Meeting, May 29 to June 2, Chicago, IL, 2015 J Clin Oncol, 33(suppl), 2015 abstract 8028.
22. 22 Besse, B., Johnson, M., Jänne, P., et al. Phase II, single-arm trial (BIRCH) of atezolizumab as first-line or subsequent therapy for locally advanced or metastatic PD-L1-selected non-small cell lung cancer (NSCLC). Proffered paper session presented at the European Cancer Congress, Vienna, Austria, abstract 16LBA, 2015.
23. 23 Fehrenbacher, L., Spira, A., Ballinger, M., et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet, 2016, 10.1016/S0140-6736(16)00587-0 [E-pub ahead of print].
24. 24 Vansteenkiste, J., Fehrenbacher, L., Spira, A., et al. Atezolizumab monotherapy vs docetaxel in 2L/3L non-small cell lung cancer: primary analyses for efficacy, safety and predictive biomarkers from a randomized phase II study (POPLAR). Proffered paper session presented at the European Cancer Congress, Vienna, Austria, abstract 14LBA, 2015.
25. 25 Spira, A., Park, K., Mazieres, J., et al. Efficacy, safety and predictive biomarker results from a randomized phase II study comparing atezolizumab (MPDL3280A) vs docetaxel in 2L/3L NSCLC (POPLAR). Poster presented at the 51st American Society of Clinical Oncology (ASCO) Annual Meeting, May 29-June 2, Chicago, IL, 2015 J Clin Oncol, 33(suppl), 2015 abstract 8010.
26. 26 Rizvi, N., Brahmer, J., Ou, S.-H., et al. Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC). Poster presented at the 51st American Society of Clinical Oncology (ASCO) Annual Meeting, May 29 to June 2, Chicago, IL, 2015 Cancer Immunol Res, 4, 2016 abstract A047.
27. 27 Antonia, S., Goldberg, S., Balmanoukian, A., et al. Phase Ib study of MEDI4736, a programmed cell death ligand-1 (PD-L1) antibody, in combination with tremelimumab, a cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) antibody, in patients (pts) with advanced NSCLC. Poster presented at the 51st American Society of Clinical Oncology (ASCO) Annual Meeting, May 29-June 2, Chicago, IL, 2015 J Clin Oncol, 33(suppl), 2015 abstract 3014.
28. 28 Gulley, J.L., Spigel, D., Kelly, K., et al. Avelumab (MSB0010718C), an anti-PDL1 antibody, in advanced NSCLC patients: a phase 1b, open-label expansion trial in patients progressing after platinum-based chemotherapy. J Clin Oncol, 33(suppl), 2015 abstract 8034.
29. 29 Rizvi, N., Shepherd, F., Antonia, S., et al. First-line monotherapy with nivolumab (anti-PD-1; BMS-936558, ONO-4538) in advanced non-small cell lung cancer (NSCLC): safety, efficacy and correlation of outcomes with PD-L1 status. Poster presented at the 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology, October 30-November 1, Chicago, IL, USA, 2014 J Radiat Oncol Biol Phys, 90(suppl), 2014, S31.
30. 30 Luis, P., Horn, L., Borghaei, H., et al. Phase III, randomized trial (CheckMate 057) of nivolumab versus docetaxel in advanced non-squamous (non-SQ) cell non-small cell lung cancer (NSCLC). Poster presented at the 51st American Society of Clinical Oncology (ASCO) Annual Meeting, May 29-June 2, Chicago, IL, USA, 2015 J Clin Oncol, 33(suppl), 2015 abstract LBA109.
31. 31 Antonia, S., Brahmer, J., Gettinger, S., et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy (PT-DC) in advanced non-small cell lung cancer (NSCLC). Poster presented at the 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology, October 30-November 1, Chicago, IL, USA, 2014 J Clin Oncol, 32(suppl), 2014, 5s.
32. 32 Sundar, R., Cho, B.-C., Brahmer, J.R., Soo, R.A., Nivolumab in NSCLC: latest evidence and clinical potential. Ther Adv Med Oncol 7 (2015), 85–96.
33. 33 Rizvi, N., Garon, E., Leighl, N., et al. Optimizing PD-L1 as a biomarker of response with pembrolizumab (MK-3475) as first-line therapy for PD-L1–positive metastatic non-small cell lung cancer (NSCLC): updated data from KEYNOTE-001. Poster presented at the 51st American Society of Clinical Oncology (ASCO) Annual Meeting, May 29-June 2, Chicago, IL, 2015 J Clin Oncol, 33(suppl), 2015 abstract 8026.
34. 34 Goldberg, S.B., Balmanoukian, A., Chaft, J., et al. A phase 1b study to evaluate the safety and antitumor activity of MEDI4736 in combination with tremelimumab in patients with advanced NSCLC. Poster presented at the European Cancer Congress, Vienna, Austria, abstract 3086, 2015 Eur J Cancer, 51(suppl 3), 2015, S627.
35. 35 Patel, S.P., Kurzrock, R., PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther 14 (2015), 847–856.
36. 36 McLaughlin, J., Han, G., Schalper, K.A., et al. Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer. JAMA Oncol 2 (2015), 1–9.
37. 37 Sharpe, A.H., Wherry, E.J., Ahmed, R., et al. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol 8 (2007), 239–245.
38. 38 Parsa, A.T., Waldron, J.S., Panner, A., et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med 13 (2007), 84–88.
39. 39 Song, M., Chen, D., Lu, B., et al. PTEN loss increases PD-L1 protein expression and affects the correlation between PD-L1 expression and clinical parameters in colorectal cancer. PLoS One, 8, 2013, e65821.
40. 40 Marzec, M., Zhang, Q., Goradia, A., et al. Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proc Natl Acad Sci U S A 105 (2008), 20852–20857.
41. 41 Akbay, E.A., Koyama, S., Carretero, J., et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov 3 (2013), 1355–1363.
42. 42 Latchman, Y.E., Liang, S.C., Wu, Y., et al. PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. Proc Natl Acad Sci U S A 101 (2004), 10691–10696.
43. 43 Madore, J., Vilain, R.E., Menzies, A.M., et al. PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials. Pigment Cell Melanoma Res 28 (2015), 245–253.
44. 44 Hansen, A.R., Siu, L.L., PD-L1 testing in cancer: challenges in companion diagnostic development. JAMA Oncol 2 (2016), 15–16.
45. 45 Kerr, K.M., Tsao, M.S., Nicholson, A.G., et al. Programmed death-ligand 1 immunohistochemistry in lung cancer: in what state is this art?. J Thorac Oncol 10 (2015), 985–989.
46. 46 Horn, L., Spigel, D., Gettinger, S., et al. Clinical activity, safety and predictive biomarkers of the engineered antibody MPDL3280A (anti-PDL1) in non-small cell lung cancer (NSCLC): update from a phase Ia study. Poster presented at the 51st American Society of Clinical Oncology (ASCO) Annual Meeting, May 29-June 2, Chicago, IL, USA, 2015 J Clin Oncol, 33(suppl), 2015 abstract 8029.
47. 47 Kohrt, H.E., Colevas, A.D., Houot, R., et al. Targeting CD137 enhances the efficacy of cetuximab. J Clin Invest 124 (2014), 2668–2682.
48. 48 Redmond, W.L., Linch, S.N., Kasiewicz, M.J., Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity. Cancer Immunol Res 2 (2014), 142–153.
49. 49 Kuchroo, V.K., Umetsu, D.T., DeKruyff, R.H., et al. The TIM gene family: emerging roles in immunity and disease. Nat Rev Immunol 3 (2003), 454–462.
50. 50 Goldberg, M.V., Drake, C.G., LAG-3 in cancer immunotherapy. Curr Top Microbiol Immunol 344 (2011), 269–278.
51. 51 Huang, R.R., Jalil, J., Economou, J.S., et al. CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans. Clin Cancer Res 17 (2011), 4101–4109.
52. 52 Ng Tang, D., Shen, Y., Sun, J., et al. Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy. Cancer Immunol Res 1 (2013), 229–234.
53. 53 Snyder, A., Makarov, V., Merghoub, T., et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 371 (2014), 2189–2199.
54. 54 Wolchok, J.D., Kluger, H., Callahan, M.K., et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369 (2013), 122–133.
55. 55 Larkin, J., Chiarion-Sileni, V., Gonzalez, R., et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373 (2015), 23–34.
56. 56 Tumeh, P.C., Harview, C.L., Yearley, J.H., et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515 (2014), 568–571.
57. 57 Choudhury, N., Yap, K., Kiyotani, K., et al. Tumor T-cell receptor (TCR) diversity elucidates the immune response to genetic alterations of muscle-invasive bladder cancer. Poster presented at the Proceedings of the 106th Annual Meeting of the American Association for Cancer Research, April 18-22, Philadelphia, PA, 2015 Cancer Res, 75, 2015, 4899.
58. 58 Vogelstein, B., Papadopoulos, N., Velculescu, V.E., et al. Cancer genome landscapes. Science 339 (2013), 1546–1558.
59. 59 Govindan, R., Ding, L., Griffith, M., et al. Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell 150 (2012), 1121–1134.
60. 60 Hellmann, M., Creelan, B., Woo, K., et al. Smoking history and response to nivolumab in patients with advanced NSCLCs. Ann Oncol 25:suppl 4 (2014), iv426–v470.
61. 61 Gettinger, S., Hellmann, M., Shepherd, F., et al. First-line monotherapy with nivolumab (NIVO) in advanced non-small cell lung cancer (NSCLC): safety, efficacy, and biomarker analyses. Poster presented at the European Cancer Congress, Vienna, Austria, abstract 3096, 2015 Eur J Cancer, 51(suppl), 2015, S632.
62. 62 Rizvi, N.A., Hellmann, M.D., Snyder, A., et al. Cancer immunology: mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348 (2015), 124–128.
63. 63 Yap, K.L., Kiyotani, K., Tamura, K., et al. Whole-exome sequencing of muscle-invasive bladder cancer identifies recurrent mutations of UNC5C and prognostic importance of DNA repair gene mutations on survival. Clin Cancer Res 20 (2014), 6605–6617.
64. 64 Le, D.T., Uram, J.N., Wang, H., et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372 (2015), 2509–2520.